Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs.
about
The alkaloid alstonine: a review of its pharmacological propertiesEvaluation of the clinical efficacy of asenapine in schizophreniaInhibition of human alpha1E subunit-mediated ca2+ channels by the antipsychotic agent chlorpromazineChlorpromazine inhibits store-operated calcium entry and subsequent noradrenaline secretion in PC12 cellsAntipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotectionPredictive animal models of mania: hits, misses and future directions.Behavioral and neurobiological changes in C57BL/6 mouse exposed to cuprizone: effects of antipsychotics.Peripheral and central adrenoceptor modulation of the behavioural effects of clozapine in the paw test.Evaluation of the behavioral and pharmacokinetic profile of SYA013, a homopiperazine analog of haloperidol in ratsPaliperidone extended-release: safety and tolerability from a metabolic profile perspective.Evaluation of the potential of antipsychotic agents to induce catalepsy in rats: assessment of a new, commercially available, semi-automated instrument.Changes in the pattern of brain-derived neurotrophic factor immunoreactivity in the rat brain after acute and subchronic haloperidol treatment.New arylpiperazinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and dihydro[1,3]oxazolo[2,3-f]purinedione targeting the serotonin 5-HT1A /5-HT2A /5-HT7 and dopamine D2 receptors.Beta-amyloid treatment sensitizes mice to amphetamine-induced locomotion but reduces response to caffeine.Atypical and typical neuroleptic treatments induce distinct programs of transcription factor expression in the striatum.Novel tricyclic[2,1-f]theophylline derivatives of LCAP with activity in mouse models of affective disorders.Preclinical Effects of Antipsychotic Drugs.
P2860
Q24538432-9F3FD4B9-D645-4BE8-8491-7C779C4E02ECQ24630385-EB9FCA51-D587-4849-B2AF-768A156378DCQ28208129-81F80896-DE66-4262-A544-E4176D1BD859Q28346378-3B7CBB5D-5BB0-462E-B293-BDD6A61D41A0Q30386608-151FE444-76A5-4FCE-8EA9-B696FAA054AFQ30462823-011EDDE6-9DC6-47AC-BF55-FDF0C062C0CCQ30482602-D6DD5047-F316-47E2-993B-83DEBBF8BD7BQ34059589-07227A21-3730-481B-BD55-676AF87E5679Q36059043-144143CE-85E3-4498-AE01-71994830F2B8Q38163397-6CA1FEDE-232C-44E0-AE15-8AD0501220AEQ38835759-826EDC6B-ABE5-4F98-8D9D-265BBF7AEA78Q43509565-BC9DF9CD-7D9C-406A-A3F8-C1EC944CA5CBQ48095780-F73B8C1B-A0D0-438B-B410-30BB500FD17AQ48447181-5A2506AF-77A0-43D2-90B3-80DA303B3244Q48892221-C700EB2A-519E-4A77-86D3-87228FDA45DEQ50627303-AB5E6E26-17FA-4435-96B9-6E584C39007DQ53779310-7FFD195A-8256-48A9-BFA8-A8D469F6A7CC
P2860
Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs.
@en
type
label
Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs.
@en
prefLabel
Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs.
@en
P1476
Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs.
@en
P2093
Ellenbroek BA
P356
10.1016/0163-7258(93)90036-D
P577
1993-01-01T00:00:00Z